Lab-Life

Many headlines stated today that UK wants to tax pharmaceutical companies again in order to contribute to a pooled fund against antimicrobial resistance (AMR). The proposed ‘pay or play’ mechanism is a bit more subtle than that. The report ( full text here) is also suggesting other financing mechanisms (including the improvement of existing ones) as well as describing potential non-financial measures to reduce these resistances in the first place. Actually, financial measures occupy only about 6% of the report. But headlines need to be catchy. Let’s see a broader picture on tackling antibiotic resistance … ...

… At least in the minds of people. Marketing is a powerful persuasion tool and you sometimes need a few early applications to create the impression that something radically new came and is changing an area. I like to listen to podcast while doing repetitive activities that don’t require my brain too much. One of the podcasts I listen to is the Clinical Air from the Pharma Talk serie. A few weeks ago, I listened to episode #14 about consumer electronics in clinical research. It was all about the Apple HealthKit. In a sense it was very interesting to hear about it as it contained more details than its Wikipedia page for the moment ; another top-level summary of its capabilities is found in this Rahlyn Gossen’s blog post (Rahlyn was one of the guests of this episode). Episode #14 was published on July 21, 2015. ...

2013 is near its end and it’s time to see what happened during the last 360 days or so. Many things happened (graduated from MBA, new house, holidays, ill a few days, …) but I wanted to know if one could quantify these changes and how these changes would impact my daily physical activity. For that purpose I bought a Fitbit One in March 2013. I chose Fitbit over other devices available because of the price (99 USD at the time) and because it was available in Europe (via a Dutch vendor). At that time the Jawbone Up was unavailable (even in the USA) and the Nike Fuelband couldn’t track my sleep. ...

I work in a company that shifted from being R&D-driven to being project-driven. It is official since this 2013 but we saw it coming: the main pieces of memory are Powerpoint slides since a few years. Everything is in Powerpoint, from agendas, discussions, presentations to minutes. Even when modelers want to show some results, they put them on a slide deck first … For presentations I used to use Beamer but installing the LaTeX toolchain on a restricted, company-owned Windows laptop was a long and cumbersome process. I made a first presentation in Reveal.js this week. And I love it! ...

The Open Knowledge Foundation (OKF) released the Open Data Index, along with details on how their methodology. The index contains 70 countries, with UK having the best score and Cyprus the worst score. In fact the first places are trusted by the UK, the USA and the Northern European countries (Denmark, Norway, Finland, Sweden). And Belgium? Well, Belgium did not score very well: 265 / 1,000. The figure below shows its aggregated score (with green: yes, red: no, blue: unsure). ...

A few months ago Google decided to retire its Google Reader (it stopped working on July 1st, 2013). As it was simple, effective and good-looking, a lot of people complained about this demise. A few days ago The Old Reader, one of the most successful replacement for Google Reader, also announced it will close its gates, only to keep early registered users. And today Feedly, another successful alternative, announced it is introducing a pro version at 5.00 USD per month. ...

I was trying to reproduce the map of the GAVI Alliance eligible countries (btw I was surprised India is eligible - but that’s the beauty of relying on numbers only and not assumptions) in R. This is the original map (there are 57 countries eligible): I started to use the R package rworldmap because it seemed the most appropriate for this task. Everything went fine. Most of the time was spent converting the list of countries from plain English to plain “ISO3” code as required (ISO3 is in fact ISO 3166-1 alpha-3). I took my source from Wikipedia. ...

As WHO and other organisations are celebrating World Diabetes Day (WDD) it is always sad to read that a new potential drug is stopped. This time Merck & co. stopped the clinical trial MK-0431E studying the co-administration of Sitagliptin and Atorvastatin in inadequately controlled Type 2 Diabetes Mellitus. Merck cites “business reasons” without further explanations. Sitagliptin is sold under the trade name Januvia. It is an oral antihyperglycemic and one of the (if not the) best selling product of Merck with US$975 million revenue in the third quarter of 2012. On the other hand Atorvastatin is a statin lowering blood cholesterol. It was a blockbuster for Pfizer (sold under the trade name of Lipitor) until its patent expired. ...

Happy Halloween! It’s the season for Q3 reports a bit everywhere so also in Pharma: Abbott (↑), Elan (↑), Eli Lilly (↓), Bristol-Myers Squibb (↓), Sanofi (↓), Novartis (↓), Shire (↑), AstraZeneca (↓), Merck & Co (↑), Novo Nordisk (↑), GlaxoSmithKline (↓), … ...

After the T-shirt that measures your sleep better than an app, here is idea #2: the toothbrush that provides some feedback. The idea is simple - so simple it was already applied elsewhere. The idea is to provide feedback about the quality of the way people brush their teeth. The Brushduino focuses on entertaining kids to keep them brushing at the right place for the right amount of time. Other projects (with many variants) focus specifically on time spent brushing. ...